| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | RO4929097 | CTRPv2 | pan-cancer | AAC | -0.1 | 0.07 |
| mRNA | UNC0321 | CTRPv2 | pan-cancer | AAC | -0.069 | 0.07 |
| mRNA | MI-2 | CTRPv2 | pan-cancer | AAC | -0.1 | 0.07 |
| mRNA | Erlotinib | gCSI | pan-cancer | AAC | -0.11 | 0.07 |
| mRNA | sirolimus:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.063 | 0.07 |
| mRNA | lapatinib | GDSC1000 | pan-cancer | AAC | -0.095 | 0.07 |
| mRNA | JNJ-26854165 | CTRPv2 | pan-cancer | AAC | -0.063 | 0.07 |
| mRNA | Rapamycin | CTRPv2 | pan-cancer | AAC | -0.063 | 0.07 |
| mRNA | L-685458 | CCLE | pan-cancer | AAC | -0.089 | 0.08 |
| mRNA | ATRA | GDSC1000 | pan-cancer | AAC | -0.063 | 0.08 |